Skip to main content
. 2022 Oct 31;12(10):e061976. doi: 10.1136/bmjopen-2022-061976

Table 1.

Data collection variables

From clinical history
  • Demographics: age, sex, date of birth and self-identified race

  • A medical history (eg, cardiac disease, bronchial asthma, eczema)

  • Previous ED visits for anaphylaxis

  • Current anaphylaxis augmenting factors (eg, physical exercise, viral illness or fever, menses in female, drugs such as non-steroidal anti-inflammatory drugs, antacid, ß-blockers and ACE inhibitors)

  • Allergen trigger (eg, type, time of exposure and onset of symptoms, location)

From physical examination
  • Participant weight

  • Vital signs at triage (heart rate, respiratory rate, blood pressure, and oxygen saturation)

  • Triage score (based on Canadian Paediatric Triage and Acuity Scale)

  • Physical exam findings on arrival at ED

From prehospital and initial ED intervention, and disposition
  • Treatment interventions (eg, epinephrine, bronchodilators) received before arrival at ED and during transport by paramedics (if applicable)

  • Non-pharmacological/supportive interventions (such as intubation and intravenous fluids) and timeline

  • Pharmacological interventions (including dose, route, frequency and time administered)

  • Disposition time, location (home or hospitalisation), list of discharge medications and outpatient allergy referral

From ED monitoring period
  • Presence and description of new/recurrent symptoms/signs

  • Time of new recurring symptoms/signs

  • Management interventions given for biphasic reaction

From follow-up email/phone call after ED disposition
  • Presence and description of new/recurrent symptoms/signs

  • Time of new/recurrent symptoms/signs

  • Management interventions given for biphasic reaction, including visits to ED/primary care providers

From 6 month follow-up (if applicable)
  • If patient was seen by allergist

  • If seen by Allergist, was allergic agent identified?

ED, emergency department.